Posters
Informational Posters - 3
October 24, 2026 | 10:00 AM - 12:00 PM
Location: Exhibit Hall A, Convention Center
Session Description
Poster Session
Note: Continuing education credits are not being offered for this session.
Posters
Navigating the National Institute of Diabetes and Digestive and Kidney Diseases
Training and Career Development Programs from the National Institute of Diabetes and Digestive and Kidney Diseases
Research Resources and Funding Opportunities for Clinical, Epidemiologic, Basic, and Translational Kidney Research from the National Institute of Diabetes and Digestive and Kidney Diseases
LUMINA: A Phase 2 Trial in Progress Evaluating the Safety and Efficacy of Obecabtagene Autoleucel in Severe, Refractory Systemic Lupus Erythematosus with Active Lupus Nephritis
Deep South Kidney, Urology and Nonmalignant Hematology Premier Research and Interdisciplinary Mentored Education (PRIME)
Study Design of the Pivotal Phase 3, Randomized, Placebo-Controlled Trial (A.M.IgA): Efficacy and Safety of Mezagitamab for the Treatment of Primary IgAN
Zigakibart and Atrasentan Combination Therapy in Patients with IgAN: Design of a Phase 3b Randomized Controlled Trial (LUMINA IgAN)
A Phase 2, Open-Label Trial to Examine Kidney Tissue-Specific Effects of Felzartamab in Adults with IgAN
Pegcetacoplan Use in Adults and Adolescents with FSGS: Rationale and Design of a Sequential Phase 2/3 Study
A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of ALXN1920 in Adults with Primary Membranous Nephropathy
IgAN Insights from Treatment Experience (IgNITE): A Multicountry Integrated Framework to Advance Real-World Evidence in IgAN
Tissue-Targeted Complement Inhibition in Rare Kidney Diseases: A Phase 2 Open-Label Basket Trial of Ebribafusp Alfa
A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Jade101 in Participants with IgAN
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Jade101 Administered Subcutaneously in Participants with IgAN
PODOMOUNT-pFSGS: Design of a Phase 3 Trial of TRPC6 Inhibitor Apecotrep in Adults and Adolescents with Primary or Genetic FSGS
PODOMOUNT-Basket: Rationale and Design of a Phase 2 Basket Trial of TRPC6 Inhibitor Apecotrep in Patients with One of Four Proteinuric Glomerular Diseases
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex-Membranoembranoproliferative Glomerulonephritis: PRISM-C3, a Multicountry Phase 4 Study
A Phase 2 Trial of Praliciguat Therapy in Patients with FSGS
Aurora: A Multi-Site Clinical Implementation Network for IgA Nephropathy
The PIONEER Trial: Expanding Evaluation of Atacicept, a B-Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) Inhibitor, to Pediatric Patients with IgAN
Listening to Patients to Build a Patient-Centered Outcomes Agenda for IgAN: A Prospective Qualitative Study Protocol